These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 21391891)

  • 1. Overcoming drug resistance in pancreatic cancer.
    Long J; Zhang Y; Yu X; Yang J; LeBrun DG; Chen C; Yao Q; Li M
    Expert Opin Ther Targets; 2011 Jul; 15(7):817-28. PubMed ID: 21391891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Binenbaum Y; Na'ara S; Gil Z
    Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
    El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
    Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pancreatic cancer--mechanisms of chemoresistance].
    Borowa-Mazgaj B
    Postepy Hig Med Dosw (Online); 2016 Mar; 70():169-79. PubMed ID: 26943314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer stem cells: emerging target for designing novel therapy.
    Li Y; Kong D; Ahmad A; Bao B; Sarkar FH
    Cancer Lett; 2013 Sep; 338(1):94-100. PubMed ID: 22445908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
    Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
    BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
    Wang Z; Li Y; Kong D; Banerjee S; Ahmad A; Azmi AS; Ali S; Abbruzzese JL; Gallick GE; Sarkar FH
    Cancer Res; 2009 Mar; 69(6):2400-7. PubMed ID: 19276344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of drug resistance in the management of pancreatic cancer.
    Sheikh R; Walsh N; Clynes M; O'Connor R; McDermott R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1647-61. PubMed ID: 20942635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
    Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
    Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
    El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
    Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
    Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
    Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic targets for pancreatic cancer.
    Tang SC; Chen YC
    World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
    Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Holistic Approaches for Overcoming Therapy Resistance in Pancreatic and Colon Cancers.
    Sarkar FH
    Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):3-10. PubMed ID: 26228733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular alterations contributing to pancreatic cancer chemoresistance.
    Rajabpour A; Rajaei F; Teimoori-Toolabi L
    Pancreatology; 2017; 17(2):310-320. PubMed ID: 28065383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
    Ozaki T; Yu M; Yin D; Sun D; Zhu Y; Bu Y; Sang M
    BMC Cancer; 2018 Mar; 18(1):309. PubMed ID: 29558908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
    Sahin IH; Iacobuzio-Donahue CA; O'Reilly EM
    Expert Opin Ther Targets; 2016; 20(3):341-59. PubMed ID: 26439702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.